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Approximately 16 genital HPV types; HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 82 , have been identified as high risk type which usually associated with high grade lesions and cancer cells. HPV 16 is the most common type related to malignant tumor and their precursor lesions, whereas the low risk HPV types, such as HPV 6, 11, are mostly caused benign or non-malignant tumors and rarely found in malignancies (Walboomer et al, 1999; Munoz et al., 2003; Moody et al, 2010) .
Persistent infection of high risk HPV is the majority causes for progression to high grade lesions and cervical cancer developing. Numerous epidemiological studies found that over 90% of invasive cervical cancer cells contained HPV DNA sequences (Parkin, 2002; Gao et al., 2003; Chaturvedi, 2010; Baldez da Silva et al., 2012; ICO HPV Information center, 2014) . In additional, HPV is also reported to be associated with the other lowergenital cancers such as anus, penis, vulva, vaginal etc which showed the various incidence and prevalence of HPV infection between different region worldwide (Gao et al., 2003; Parkin, 2006; Hampl, 2007; Ramet et al., 2010; ICO HPV Information center, 2014) . Although the frequency of HPV infection in other genital intraepithelial neoplasia and cancer cells are less variety than cervical cancer, but it is the interesting epidermiological data of viral caused cancer, especially vulva and vaginal including their precursor lesions which were rare incidence among all gynecological cancer. Whereas, the incidence and mortality of vulva and vaginal invasive cancers have remained stable and the evidence of HPV infection was quiet strongly increased over the past few years (ICO HPV Information center, 2014).
Vulva and vaginal cancers are rare malignancy among women worldwide, with an accounted for 27,000 and 13,000 new cases, respectively in 2008 and represented around 2% to 4% of all gynecological cancers (de Martel et al., 2012; ICO HPV Information center, 2014) . Many studies reported that many risk factors of cervical cancer development, such as history of sexual behavior and other sexually transmitted diseases, smoking, alcohol consumption, history of HPV infection etc, were causally related with vulva and vaginal abnormality lesions and cancer cells (Trimble et al., 1996; Madeleine et al., 1997; Gillison, 2003) . Approximately 60% of all vulva cancer cases were found in developed countries, conversely the majority of vaginal cancer could be observed in developing countries as similar to cervical cancer evidence. Vulva and vaginal cancers are common occur in elder women (>60 years) and the majority type of these cancers are squamous cell carcinoma (ICO HPV Information center, 2014; Sankaranarayanan et al., 2006; Kurunaratne, 2011) .
For Thailand evidence; The Thailand Cancer Registry on 2008 reported that the incidence of vulva and Vaginal among Thai women were limited, with age standardized incidence rate (ASR) of 0.4 and 0.2 per 100,000 Thai women, respectively (Khuhaprema et al., 2013) .
Numerous epidemiological studies have shown that there are two independent pathways have been associated with the progression of vulva abnormality lesions and cancer; the first pathway is classified as a differentiated keratinizing which is common occurs in elderly women. It also often differentiated vulva intraepithelial neoplasia (dVIN) and only 2%-23% of this type harbors HPV infection (Parkin, 2006; Trimble et al., 1996) , whereas the second pathway is often affected in younger women. It is identified as non-keratinizing type (usual VIN; uVIN) which is related with warty, basaloid or mixed type of warty and basaloid. Almost of vulva intraepithelial neoplasia with non-keratinizing types tends to be associated with high risk HPV infection (Parkin, 2006; Madeleine et al., 1997; Ramet et al., 2010; Terlou et al., 2010) . While, most of vaginal cancer cases, especially squamous cell carcinoma are generally attributed to HPV infection similar to cervical cancer and often occur in women over 50 years (ICO HPV Information center, 2014) . Moreover, some of epidermiological studies found that women with vaginal abnormality lesions (VAIN) are more likely to have a history of cervical cancer and HPV 16 is the most common type in high-grade vaginal neoplasia and malignancy as similar to vulva and cervical cancer (Parkin, 2006; Hamp et al., 2006; de Martel et al., 2012; ICO HPV Information center, 2014) .
The aim of this study was to evaluate HPV frequency and specific type-distribution from Thai women tissues with vulva and vaginal abnormality lesions and cancers. 
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Materials and Methods
Sample collection
Ninety formalin-fixed and paraffin-embedded (FFPE) tissues of vulva and vaginal abnormality lesion and cancers, which were collected, diagnosed during 2003-2012 with histological confirmed, were obtained from Specimen Bank and Pathology Department, National Cancer Institute, Thailand.
The research protocol has been reviewed and approval by Research and Ethics committee of National Cancer Institute, Thailand based on the Declaration of Helsinki and Good Clinical Practice.
Sample preparation and DNA extraction
Three to five of 5 μm thick sections of vulva and vaginal tissues from FFPE samples were collected in sterile vial. Single use blade, groves and sterile forceps were used to prevent carry-over contaminant with the different samples. After deparaffinization with xylene, twice rehydration in absolute ethanol and discharge the remaining ethanol, all of samples were dried at room temperature to ensure that no residual ethanol (Ngamkham et al., 2013) . Genomic DNA extraction was performed using QIAamp DNA Mini kit (QIAGEN, Germany) according to the manufacturer's instruction and genomic DNA quality was evaluated by polymerase-chain reaction with β-globin primers (Jacob et al., 1996) ; sense 5'-ACA CAA CTG TGT TCA CTA GC-3' and antisense 5'-GAA ACC CAA GAG TCT TCT CT-3'. Total volume of 25 μl PCR mixture was consisted of 5 μl extracted DNA, 0.4μM of sense and antisense primers, 2.5U Taq polymerase, 200nM of each dNTPs and 1.5mM MgCl 2 . The amplification was performed using GeneAmp 9700 thermal cycler (Applied Biosystemic, USA) and cyclic condition under the following; initial o C for 5 min in the final step. Amplified products were visualized on 2% agarose gel electrophoresis with UV transilluminator (SYNGENE, England).
HPV DNA detection and genotyping
HPV DNA detection and genotyping method were performed according to Jacob et al. (1997; 2000) . HPV DNA was amplified by polymerase chain reaction (PCR) using general primers GP5+/6+ (GP5+; 5'-TTT GTT ACT GTG GTA GTA ACT AC-3' and GP6+ biotin-labeled 5'-GAA AAA TAA ACT GTA AAT CAT ATT C-3') to amplify the corresponding part of HPV L1 gene and DNA from the HPV 16 positive SiHa cell line was used as a positive control. The PCR mixture contained 10μl extracted DNA, 0.4μM of each specific primer, 2.5U Taq polymerase, 200nM of each dNTPs and 1.5mM MgCl 2 and PCR condition were amplified following profile of initial denature at 94 o C, 5 min and then followed by 40 cycles of 94 o C, 1 min; 38 o C, 2 min; 72 o C, 1.30 min. The finally step was re-extension for 4 min at 72 o C. HPV genotype was identified by using Enzyme-immunoassay (EIA) with HPV specific probes for high risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and low risk HPV types (HPV 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, 71, 72, 73, 81, 82, 83, 84, and 89) , In brief, mixer solution of 5μl HPV-positive PCR product and 50μl 1xSCC, 0.5% Tween20 was added to each well of streptavidin-coated plate (Roche, Germany) and incubated at 37 o C for 60 min to completely bind biotinylated compounds. Unbound biotinylated were eliminated by three times washing with freshly prepared 1xSCC, 0.5% Tween20 solution. Then, digoxigenin labeled HPV specific probes was added and incubated for 60 min at Table I HPV DNA detection in cancer and abnormal lesion samples by PCR-EIA methods were observed that 47.06% (16/34) of vulva cancer and 40% (8/20) of vulva abnormal lesion samples shown HPV positive. About 60% (3/5) and 51.61% (16/31) of Vaginal cancers and abnormal lesion samples, respective could detect HPV DNA, as shown in Table I .
From our HPV genotype results found that single type and multiple type infection could be detected in both type of cancer or abnormal lesion samples in the different histological categorizes. In additional, the frequency of single was higher than multiple type infection and also detected in cancer cells higher than abnormal cytology lesion samples, as shown in Table II .
The most common HPV type in this study was HPV 16, accounting for 75% (12/16 samples, in which 7/16 cases were single type infection and 5/16 cases were multiple type infection) and 100% (3/3 samples; consisted of 2/3 and 1/3 were single and multiple type infection, respectively) of vulva and Vaginalcancers, respectively. Moreover, the results of genotype in abnormal lesion, HPV 16 were higher frequency than the other types. It accounted 4/8 and 9/16 samples of all vulva and vaginal abnormal lesions with HPV positive, respectively. The three common frequency type which could be detected in this study were HPV 16, 33 and 35 for vulva cancer cells and HPV 16, 33 and 58 for vulva abnormal cells, whereas HPV 16 and 31 were found in Vaginal cancer cells and HPV 16, 58, 18 and 35 were the top three frequency in Vaginal abnormal cytology lesion cells. Almost of HPV type detection samples belong to the high risk type, but the low risk type, such as HPV 6, 11 which were usually found in lower genital abnormal lesion or benign tumor, were also detected in vulva samples as co-infection with the other high risk type; such as HPV6/11/16/33, HPV 6/16 etc. However, HPV genotype in abnormal cytology lesion samples showed a wide variety of type distribution and could be detected both of high risk and low risk type, as shown in Figure I 
Discussion
Vulva and Vaginal cancers are rare gynecological cancer among women worldwide and common diagnosed in older women (over 65 years). There are many epidemiological risk factors, included persistent high risk HPV infection, were essential cause for vulva and Vaginal abnormal lesions developing or cancer cells progression (ICO HPV Information center, 2014; Karunaratne, 2011; Bharti wt al., 2010) . Although high risk HPV infection is a well-established cause of cervical cancer, but there is now growing evidence of HPV being a relevant factor in vulva and Vaginal cancers. HPV infection is associated with both of benign and malignant lesions and almost detected in the younger women rather than elder women (zur Hausen, 2002; De Vuyst et al, 2009; Ramet et al., 2010; Dittmer et al., 2011) In this study, HPV DNA detection was performed on section of paraffin-embedded biopsy. The frequency of HPV positive was detected to be 47.06% and 60% in vulva and Vaginal cancers, respectively. It was not different from results of a systematic review which was conducted by Smith et al. (2007) in which 40.1% and 65.5% of vulva and vaginal cancer samples, respectively, presented HPV DNA. While the meta-analysis of HPV prevalence in vulva, Vaginal and anal from 93 studies which was investigated by De Vuyst et al. (2009) DOI:http://dx.doi.org/10.7314/APJCP.2016 .17.3.1129 Detection and Type-Distribution of HPV in Vulval and Vaginal Abnormal Cytology Lesions and Cancers in Thai Women Vuyst et al (2009 which represented HPV prevalence approximately 60%-85% and 90% among vulva and Vaginal intraepithelial neoplasia, respectively, suggested that vulva and Vaginal sample with abnormal lesions in this study did not specific recruited only abnormal cytology tissues with intraepithelial lesions (VIN or VAIN) as similar to the criteria of two those previous studies. All of these tissues with abnormal cytology were random investigated in various histopathology types such as chronic inflammation, Leiomyoma etc, including intraepithelial neoplasia and some of vulva tissues with keratinizing histological type such as lichen sclerosus was likely to be non-HPV-related and usually found in older women. (ICO WHO Information center, 2014; Smith et al., 2007; Madeleine et al., 1997) Furthermore, not all of vulva and Vaginal cancers are induced by HPV, it dependent on the several factors such as age, cancer history, type of cancer diagnosed, etc (Hampl et al., 2006) . However, our results of HPV DNA showed that 1/1 sample of vulva intraepithelial neoplasia (VIN) and 3/3 samples of Vaginal intraepithelial neoplasia (VAIN) in this study found HPV infection.
HPV 16 is the most common genotype identified in this study as similar to the other reports (ICO WHO Information center, 2014; Ramet et al., 2010; Giuliano et al., 2008; Hampl et al., 2007) . It represented 12/16 (75%), 4/8 (50%), 3/3 (100%) and 9/16 (56.25%) in vulva cancer, vulva abnormal lesions, Vaginal cancer and Vaginal abnormal lesion samples, respectively. The most three common HPV types which was detected in vulva cancer and abnormal lesions were 16, 33, 35 and 16, 33, 58, respectively whereas HPV 16, 33 and HPV 16, 58, 18, 35 were found higher frequency than the other types in Vaginal tissues with cancer and abnormal lesions, respectively. And we observed that HPV 18 could be detected as co-infection with other high risk types and all of low risk type was never found as single infection in this study. Although the most three common HPV typedistribution in vulva and Vaginal in our study showed slightly different from the other reports (Ramet et al, 2010; ICO WHO Information center, 2014; Hampl et al., 2007; Baldez da Silva et al., 2012) , due to the different HPV detection methods, amount or type of sample collection, population characteristic, etc, but there are several studied reported which found that high risk HPV type such as HPV 16, 18, 31, 33, 35, 45, 51, 52, 56 or 58 have been associated with vulva, vagina, penis, anus or cervical cancers and abnormal lesions (Giuliano et al., 2008; Baldez da Silva et al., 2012; Hampl et al., 2007; De Vuyst et al., 2009 Otherwise, the variety of population group, sample selection and histological diagnosis results were to be the important factors which were used to be considerable (Hampl et al., 2006; Giuliano et al., 2008) This finding demonstrated that HPV 16 was the most common HPV type present in vulva and Vaginal tissues with abnormal cytology lesions and cancer cells while HPV 18 and the other types showed less frequently for both organs from Thai women and the HPV type distribution of vulva and Vaginal were not variety as cervical cells. However, it is interesting baseline data on HPV prevalence of vulva and Vaginal abnormal/cancer from Thai women, which there are limited evidences available and both of these cancers are more less frequency compared to cervical cancer, although the sample size in this study was small and did not represented overall incidence and prevalence of Thai women population. Moreover, persistent high risk HPV infection is the effective factor that causes the abnormal or cancer cells of genital tract development, the efficiency prevention programs which reinforce the HPV detection and vaccination may decrease the incidence of HPV-associated diseases in the nearly future.
